Odyssey Therapeutics (NASDAQ:ODTX) Earns Outperform Rating from Analysts at Wedbush

Research analysts at Wedbush started coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a research note issued to investors on Tuesday, Marketbeat reports. The brokerage set an “outperform” rating and a $30.00 price target on the stock. Wedbush’s price target points to a potential upside of 76.89% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Odyssey Therapeutics to a “hold” rating in a report on Saturday, May 16th. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They set an “overweight” rating for the company. TD Cowen assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They set a “buy” rating for the company. Finally, Oppenheimer assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They set an “outperform” rating and a $40.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $32.00.

Odyssey Therapeutics Price Performance

Shares of NASDAQ ODTX opened at $16.96 on Tuesday. Odyssey Therapeutics has a 1 year low of $15.35 and a 1 year high of $20.30.

Insider Activity at Odyssey Therapeutics

In other news, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the transaction, the insider directly owned 1,831,383 shares of the company’s stock, valued at approximately $32,964,894. This trade represents a 43.54% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dimension Capital Ii, L.P. purchased 1,111,111 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the transaction, the director directly owned 3,333,516 shares of the company’s stock, valued at $60,003,288. This represents a 50.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 4,183,777 shares of company stock valued at $75,319,986 over the last three months.